Manali Patki

Manali Patki

Auto-generated profile, based on publicly available information

Manali Patki

College of Pharmacy and Health Sciences, St. John's University, Queens, New York, USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 January 2019 in AAPS PharmSciTech
Verified
Journal Article
Closed access
PDF file
PNPavan Kumar Nukala
Pavan Kumar Nukala
SPSiddhant Palekar
Siddhant Palekar
MPManali Patki
Manali Patki
KPketankumar patel
ketankumar patel

1 May 2020 in European Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
RVRicha Vartak
Richa Vartak
SMSuvidha Menon
Suvidha Menon
MPManali Patki
Manali Patki
BBBlase Billack
Blase Billack
KPketankumar patel
ketankumar patel

1 February 2019 in Journal of 3D Printing in Medicine
Verified
Journal Article
Closed access
PNPavan Kumar Nukala
Pavan Kumar Nukala
SPSiddhant Palekar
Siddhant Palekar
NSNayan Solanki
Nayan Solanki
YFYige Fu
Yige Fu
MPManali Patki
Manali Patki
KPKetan Patel
Ketan Patel

2 December 2018 in Drug Development and Industrial Pharmacy
Verified
Journal Article
Closed access
MPManali Patki
Manali Patki
KPKetankumar Patel
Ketankumar Patel
Background: Recrystallization of drug and incomplete drug release from liquisolid formulation are two major hurdles in the development of a supersaturated self-nanoemulsifying drug delivery system. The aim of this research work was to develop a solid supersaturated self-nanoemulsifying drug delivery system of fenofibrate (FB) for enhanced dissolution. Methods: FB loaded supersaturated self-nanoemulsifying preconcentrate (superSNEP) was prepared using dimethyl acetamide (DMA), medium chain triglycerides (MCT) and kolliphor EL. Co-processed excipients (CPE) prepared using inorganic microporous silica (Neusilin US2, Florite 100 or Aerosil 200) and hydrophilic polymers (Polyvinyl alcohol, HPMC and Kollidon VA64) were evaluated for flow property, BET surface area and adsorption capacity. Lipophilic fluorescent probe (coumarin-6) was used to investigate the extent of self-emulsification. The formulation was further characterized for solid state, in-vitro cytotoxicity in caco-2 cell line and in-vitro dissolution in a sink and non-sink conditions. Results: Optimized superSNEP with 20% w/v FB loading spontaneously formed nanoglobules of 40 ± 2.7 nm. DMA based self-nanoemulsifying system was found to be non-toxic to Caco-2 cell even at a very high concentration. CPE prepared using PVA and Florite 100 (1:1 weight ratio) showed the highest adsorption capacity (1 mL/g) and complete release of oil as depicted by fluorescence study. DSC thermogram and PXRD of S-superSNEP confirmed that FB remained in a solubilized state. S-superSNEP showed significantly faster and higher dissolution of FB in sink and non-sink conditions compared to the plain API. Conclusion: DMA and PVA-F100 based novel co-processed excipient could be potentially useful for the development of solid supersaturated self-nanoemulsifying drug delivery system for enhancing dissolution of lipophilic drugs.

14 July 2019 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
MPManali Patki
Manali Patki
KGKiersten Giusto
Kiersten Giusto
SGSamir Gorasiya
Samir Gorasiya
SRSandra Reznik
Sandra Reznik
KPketankumar patel
ketankumar patel
Preterm birth (PTB) is a major cause of infant mortality in the United States and around the globe. Makena®—once-a-week intramuscular injection of 17-α Hydroxyprogesterone caproate (17P)—is the only FDA approved treatment for the prevention of PTB. Invasive delivery of 17P requires hospitalization and expert personnel for injection. Vaginal delivery of 17P would be preferable, because of high patient compliance, reduced systemic exposure, fewer side effects, and no need for hospitalization. The objective of the present study was to prepare and evaluate a self-nanoemulsifying vaginal tablet of 17P. A solid self-nanoemulsifying preconcentrate (S-SNEDDS) of 17P and dimethylacetamide (DMA) was developed using medium chain triglycerides, a non- immunogenic surfactant, and co-processed excipient (PVA-F100). The tablet prepared was characterized for emulsification time, particle size, solid state properties, and drug release. The formulation showed >50% inhibition of TNF-α release from LPS-stimulated RAW 264.7 cells. Importantly, there were significant differences in rates of PTB and average time to delivery between control and vaginal 17P-treated groups in LPS-stimulated timed pregnant E15.5 mice. Considering the lacuna of therapeutic approaches in this area, vaginal delivery of 17P for the prevention of preterm birth has significant clinical relevance.

1 October 2019 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
PNPavan Kumar Nukala
Pavan Kumar Nukala
SPSiddhant Palekar
Siddhant Palekar
MPManali Patki
Manali Patki
YFYige Fu
Yige Fu
KPketankumar patel
ketankumar patel